The strong and durable 52-week OLE data de-risks the upcoming U.S. AURORA Phase 3 trial, while the ATM termination removes a near-term dilution overhang. The key catalyst to watch is the initiation of AURORA patient screening in October 2026 and subsequent enrollment updates.
Price Chart
Executive Summary
Sagimet announced positive 52-week results from the Phase 3 open-label extension trial (ASC40-304) of denifanstat in moderate-to-severe acne, conducted by partner Ascletis in China. The OLE showed sustained efficacy (56.7% treatment success rate, ~72% total lesion reduction) with a favorable safety profile. Separately, Sagimet terminated its ATM prospectus supplement, removing near-term dilution overhang. Patient screening for the U.S. AURORA Phase 3 trial is expected to begin in October 2026.
Key Facts
- Denifanstat OLE (ASC40-304) showed 56.7% treatment success rate, 71.8% mean reduction in total lesion count, and 76.9% reduction in inflammatory lesion count at 52 weeks.
- No drug-related serious adverse events or permanent discontinuations in the OLE; only dry skin (7.1%) and dry eye (5.9%) had >5% incidence.
- Patient screening for U.S. AURORA Phase 3 trial (800 patients, 2:1 randomization) expected to begin in October 2026.
- ATM prospectus supplement terminated effective September 30, 2026, removing near-term dilution risk.
- Cash position of $257.6M as of June 30, 2026, expected to fund operations through 2028 and through denifanstat Phase 3 readout.
- Denifanstat NDA for acne accepted by China NMPA in December 2025.
Financial Impact
No revenue or earnings reported. Cash position of $257.6M as of 6/30/2026. ATM termination removes potential dilution.
Risk Factors
- U.S. Phase 3 AURORA trial may not replicate Chinese Phase 3 results due to different population or regulatory standards.
- Denifanstat has not yet been approved by the FDA; clinical and regulatory risks remain.
- MASH development is contingent on securing non-dilutive funding, which is uncertain.
- Competition from existing acne therapies and other novel mechanisms could limit market uptake if approved.
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-408224 |
| Document: d96035dex992.htm | 0001193125-26-408224 |
| Document: d96035d8k.htm | 0001193125-26-408224 |
| Document: 0001193125-26-408224-index-headers.html | 0001193125-26-408224 |
| Document: 0001193125-26-408224-index.html | 0001193125-26-408224 |
| Document: 0001193125-26-408224.txt | 0001193125-26-408224 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $9.95 $9.58 | ▼ −3.72% | ▼ −3.20% | $10.42 (+4.72%) |
Oct 7, 2026 19d ago | SC 13G | $8.92 $8.93 | ▲ +0.11% | ▼ −0.49% | $10.42 (+16.82%) |
Oct 1, 2026 26d ago | Press Release | $9.14 $9.03 | ▲ +1.20% | ▲ +1.88% | $10.42 (−14.00%) |
Sep 30, 2026 27d ago | Press Release | $9.88 $9.37 | ▲ +5.16% | ▲ +5.34% | $10.42 (−5.47%) |
Sep 30, 2026 27d ago | 8-K | $9.88 $9.37 | ▼ −5.16% | ▼ −5.34% | $10.42 (+5.47%) |
Sep 22, 2026 5w ago | Institutional Cluster | $11.09 $10.42 | ▼ −6.04% | ▼ −5.32% | $10.42 (−6.04%) |
Aug 25, 2026 9w ago | Press Release | $10.29 $10.86 | ▲ +5.54% | ▲ +5.52% | $10.42 (+1.26%) |
Aug 11, 2026 11w ago | 8-K | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $10.42 (+9.45%) |
Aug 11, 2026 11w ago | Press Release | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $10.42 (+9.45%) |
Jul 22, 2026 13w ago | Insider Cluster | $7.01 $7.07 | ▲ +0.86% | ▲ +0.75% | $10.42 (+48.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers